Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society

This document presents the consensus recommendations of the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society for lipid modification in patients with ischemic stroke or transient ischemic attack. This clinical guide summarizes the current literature on lipid management and can be of assistance to the physicians treating stroke patients in clinical practice.

[1]  Hong Wang,et al.  Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis , 2020, Stroke.

[2]  J. Manson,et al.  Olive Oil Consumption and Cardiovascular Risk in U.S. Adults. , 2020, Journal of the American College of Cardiology.

[3]  E. Vicaut,et al.  Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke , 2020, Stroke.

[4]  J. Leal,et al.  Economic burden of stroke across Europe: A population-based cost analysis , 2019, European stroke journal.

[5]  H. Milionis,et al.  Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview , 2020, International journal of stroke : official journal of the International Stroke Society.

[6]  E. Vicaut,et al.  A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. , 2019, The New England journal of medicine.

[7]  Deepak L. Bhatt,et al.  Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES , 2019, Circulation.

[8]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[9]  S. Pocock,et al.  Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. , 2019, European heart journal.

[10]  Michael V Holmes,et al.  Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China , 2019, The Lancet.

[11]  L. Moja,et al.  Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis , 2019, BMC Medicine.

[12]  N. Martin,et al.  Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. , 2019, The Cochrane database of systematic reviews.

[13]  Jian-Min Yuan,et al.  Adherence to the Mediterranean diet and risk of stroke and stroke subtypes , 2019, European Journal of Epidemiology.

[14]  John Fuller,et al.  Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials , 2019, The Lancet.

[15]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[16]  R. de Caterina,et al.  Cholesterol lowering and stroke: no longer room for pleiotropic effects of statins - confirmation from PCSK9 inhibitor studies. , 2019, The American journal of medicine.

[17]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[18]  Jae Hyeon Park,et al.  Medication Adherence of Statin Users after Acute Ischemic Stroke , 2018, European Neurology.

[19]  D. Panagiotakos,et al.  The Role of Nutraceuticals in Statin Intolerant Patients. , 2018, Journal of the American College of Cardiology.

[20]  Sidong Yang,et al.  The beneficial role of early exercise training following stroke and possible mechanisms. , 2018, Life sciences.

[21]  T. Morimoto,et al.  Response by Yoshimura et al to Letter Regarding Article, "Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)". , 2018, Stroke.

[22]  T. Steiner,et al.  Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis , 2018, Stroke.

[23]  A. Karantanas,et al.  Recommendations for Mechanical Thrombectomy in Patients with Acute Ischemic Stroke , 2018, Clinical Neuroradiology.

[24]  T. Morimoto,et al.  Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient) , 2017, Stroke.

[25]  A. Keech,et al.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[26]  K. Furie,et al.  Smoking cessation and outcome after ischemic stroke or TIA , 2017, Neurology.

[27]  R. Giugliano,et al.  Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Circulation.

[28]  A. Keech,et al.  Cognitive Function in a Randomized Trial of Evolocumab , 2017, The New England journal of medicine.

[29]  Michael Miller,et al.  Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association , 2017, Circulation.

[30]  H. Kamel,et al.  Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation , 2017, Stroke.

[31]  B. Nordestgaard,et al.  Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study , 2017, British Medical Journal.

[32]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[33]  G. Grosso,et al.  A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal? , 2017, Critical reviews in food science and nutrition.

[34]  R. Giugliano,et al.  Cognitive Function in a Randomized Trial of Evolocumab. , 2017, The New England journal of medicine.

[35]  R. Hart,et al.  Embolic Stroke. , 2017, Circulation.

[36]  A. Mammen.  Statin-Associated Autoimmune Myopathy. , 2016, The New England journal of medicine.

[37]  E. Dolan,et al.  Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation–Related Stroke: A Population Study , 2015, Stroke.

[38]  S. Ibayashi,et al.  The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study , 2015, EBioMedicine.

[39]  H. Milionis,et al.  Embolic Strokes of Undetermined Source in the Athens Stroke Registry: An Outcome Analysis , 2015, Stroke.

[40]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[41]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[42]  C. Levi,et al.  Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial , 2015, The Lancet Neurology.

[43]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[44]  G. Lip,et al.  Statin treatment is associated with improved prognosis in patients with AF-related stroke. , 2014, International journal of cardiology.

[45]  Sung Hoon Kang,et al.  Statins Improve Survival in Patients With Cardioembolic Stroke , 2014, Stroke.

[46]  F. Hu,et al.  Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study , 2014, BMC Medicine.

[47]  N. Chalasani,et al.  An assessment by the Statin Liver Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[48]  Matthew K Ito,et al.  Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. , 2012, Journal of clinical lipidology.

[49]  Eric E. Smith,et al.  Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis , 2011, Circulation.

[50]  G. Ntaios,et al.  Temporal Distribution and Magnitude of the Vulnerability Period around Stroke Depend on Stroke Subtype , 2011, Cerebrovascular Diseases.

[51]  J. Chawla.  Stepwise Approach to Myopathy in Systemic Disease , 2011, Front. Neur..

[52]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[53]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[54]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[55]  J. Cole,et al.  Smoking and stroke: the more you smoke the more you stroke , 2010, Expert review of cardiovascular therapy.

[56]  A. Kyritsis,et al.  Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival , 2009, Neurology.

[57]  Michael G. Hennerici,et al.  Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes , 2009, Stroke.

[58]  J. Rimmer,et al.  A preliminary study to examine the effects of aerobic and therapeutic (nonaerobic) exercise on cardiorespiratory fitness and coronary risk reduction in stroke survivors. , 2009, Archives of physical medicine and rehabilitation.

[59]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[60]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[61]  L. Klein,et al.  Atherosclerosis regression, vascular remodeling, and plaque stabilization. , 2007, Journal of the American College of Cardiology.

[62]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[63]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[64]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[65]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[66]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[67]  G. MacGregor,et al.  How Far Should Salt Intake Be Reduced? , 2003, Hypertension.

[68]  R. Bernstein,et al.  Uncommon Causes of Stroke , 2002 .

[69]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[70]  J. Lekakis,et al.  The Athens Stroke Registry: Results of a Five-Year Hospital-Based Study , 2000, Cerebrovascular Diseases.

[71]  D. Grobbee,et al.  Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry. , 1999, Stroke.

[72]  G. Bollinger,et al.  Population Study , 2020, Definitions.